Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin

Background: Bisphosphonates are commonly prescribed antiresorptive agents for the management of patients with osteoporosis, Paget's disease, multiple myeloma, and metastatic tumors. Platelet-rich fibrin (PRF) is a second generation platelet concentrate, and has the ability of regulating the inf...

Full description

Saved in:
Bibliographic Details
Published in:Cranio 2017-09, Vol.35 (5), p.332-336
Main Authors: Gönen, Zeynep Burçin, Yılmaz Asan, Canay
Format: Article
Language:English
Subjects:
Aged
Bisphosphonate
Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging
Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy
Cone-Beam Computed Tomography
Dentistry
Follow-Up Studies
Humans
Male
Osteonecrosis
Platelet-Rich Fibrin
Radiography, Panoramic
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Bisphosphonates are commonly prescribed antiresorptive agents for the management of patients with osteoporosis, Paget's disease, multiple myeloma, and metastatic tumors. Platelet-rich fibrin (PRF) is a second generation platelet concentrate, and has the ability of regulating the inflammation and stimulation of chemotactic agents. The aim of this report is to present the treatment of Stage-3 bisphosphonate-related osteonecrosis of the jaw (BRONJ) by PRF. Clinical Presentation: A 77-year-old male patient with Stage-3 BRONJ was treated with minimal surgical operations and PRF membrane. The patient was followed up for 18 months, and there was no recurrence or exposure. Conclusion: PRF may promote the healing of both bone and soft tissues even in Stage-3 patients. This technique is an alternative treatment modality for the closure of bone exposure and tissue healing in BRONJ patients.
ISSN:0886-9634
2151-0903
DOI:10.1080/08869634.2016.1203093